At a glance
ClinicalIndex Comparison RecordPhase 2Terminated· 6 enrolled
Drug / intervention
Eltrombopag +1 moredrug
Likely dose
Eltrombopag 100 mgfrom record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Phase II Study of Eltrombopag in Combination With Decitabine in Subjects With Advanced Myelodysplastic Syndrome
In Brief
A Phase 2 clinical trial evaluating Eltrombopag and Decitabine for Leukemia. Terminated early, enrolled 6 participants across 1 site.
Signals
Trial was terminated early
Detailed Summary
The goal of this clinical research study is to learn if eltrombopag given in combination with decitabine can help to control advanced MDS. The safety of this study drug combination will also be studied.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsLeukemia
CountriesUnited States
CollaboratorsGlaxoSmithKline
Timeline
Phase 2TerminatedFinished
2014201520162017201820192020202120222023202420252026
First PostedDec 2013
Enrollment StartMar 2014
Primary CompletionJan 2019
TodayJul 2026
First PostedDec 13, 2013
Enrollment StartMar 1, 2014
Primary CompletionJan 2, 2019
TodayJul 1, 2026
Enrollment to primary: 4.8 yearsPosted 12.5 years ago
Interventions
Eltrombopagdrug
Starting dose of Eltrombopag is 100 mg by mouth daily for each 28 day cycle. East Asians will start at 50 mg by mouth daily for each 28 day cycle.
Decitabinedrug
Starting dose of Decitabine is 20 mg/m2 by vein on Days 1-5 for each 28 day cycle.